The drug maker behind the first FDA-approved medication derived from marijuana has revealed how much



A marijuana-derived drug that recently became the first of its kind to win federal approval is not going to be cheap.

Called Epidiolex, the drug is designed to treat two rare forms of childhood epilepsy using a cannabis compound called cannabidiol (or CBD).

On a call with investors this week, British-based GW Pharmaceuticals, who makes the drug, said it would cost roughly $32,500 per year. The medication does not contain THC, the well-known psychoactive component of marijuana responsible for the drug's characteristic high. >>>


  • LinkedIn - White Circle
21972-312_SOC_NonCPA.png
Cannabis Banking, Simplified.

Shield's purpose built compliance platform manages the risk, compliance and operational demands associated with banking in the legalized cannabis industry. With Shield's transactional and operational transparency tools, compliance officers are notified of non-compliant activity quickly. 

© 2019 Shield Compliance, LLC ||| 500 Union St., Ste 310 Seattle WA 98101

Website development and management by FI Partners, LLC